Merck KGaA 과거 수익 실적
과거 기준 확인 2/6
Merck KGaA has been growing earnings at an average annual rate of 16.5%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 7.2% per year. Merck KGaA's return on equity is 9.2%, and it has net margins of 12.6%.
주요 정보
16.5%
수익 성장률
16.5%
EPS 성장률
| Pharmaceuticals 산업 성장 | 7.3% |
| 매출 성장률 | 7.2% |
| 자기자본 수익률 | 9.2% |
| 순이익 | 12.6% |
| 다음 실적 업데이트 | 14 Nov 2024 |
최근 과거 실적 업데이트
Recent updates
Some Shareholders Feeling Restless Over Merck KGaA's (ETR:MRK) P/E Ratio
Oct 18
Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?
Sep 05Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly
Jul 24Some Confidence Is Lacking In Merck KGaA's (ETR:MRK) P/E
Jul 03Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price
May 22Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20
Apr 26Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20
Apr 04Merck KGaA (ETR:MRK) Has Affirmed Its Dividend Of €2.20
Mar 18We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
Feb 07There's Reason For Concern Over Merck KGaA's (ETR:MRK) Price
Jan 17Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 77% Above Its Share Price
Dec 27Does Merck KGaA (ETR:MRK) Have A Healthy Balance Sheet?
Oct 10Is There An Opportunity With Merck KGaA's (ETR:MRK) 49% Undervaluation?
Sep 13Is Merck KGaA (ETR:MRK) A Risky Investment?
Jun 30Are Investors Undervaluing Merck KGaA (ETR:MRK) By 36%?
Jun 09These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well
Mar 26MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20
Mar 05Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
Feb 14We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt
Dec 12Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?
Nov 09Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?
Aug 15Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?
May 17MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85
Mar 29Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?
Jan 13We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease
Oct 15A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)
Sep 19수익 및 비용 분석
수익 및 비용 분석
Merck KGaA 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 20,870 | 2,626 | 5,735 | 2,469 |
| 31 Mar 24 | 20,820 | 2,722 | 5,738 | 2,423 |
| 31 Dec 23 | 20,993 | 2,824 | 5,786 | 2,439 |
| 30 Sep 23 | 21,428 | 2,893 | 5,823 | 2,398 |
| 30 Jun 23 | 22,061 | 3,078 | 6,035 | 2,460 |
| 31 Mar 23 | 22,327 | 3,242 | 6,075 | 2,458 |
| 31 Dec 22 | 22,232 | 3,326 | 5,982 | 2,447 |
| 30 Sep 22 | 21,785 | 3,473 | 5,925 | 2,411 |
| 30 Jun 22 | 20,952 | 3,311 | 5,745 | 2,436 |
| 31 Mar 22 | 20,254 | 3,188 | 5,557 | 2,428 |
| 31 Dec 21 | 19,687 | 3,055 | 5,461 | 2,418 |
| 30 Sep 21 | 19,072 | 2,689 | 5,334 | 2,466 |
| 30 Jun 21 | 18,546 | 2,733 | 5,234 | 2,330 |
| 31 Mar 21 | 17,795 | 2,278 | 5,230 | 2,259 |
| 31 Dec 20 | 17,534 | 1,987 | 5,300 | 2,262 |
| 30 Sep 20 | 17,317 | 1,884 | 5,453 | 2,231 |
| 30 Jun 20 | 16,924 | 1,419 | 5,550 | 2,258 |
| 31 Mar 20 | 16,776 | 1,549 | 5,643 | 2,291 |
| 31 Dec 19 | 16,152 | 1,292 | 5,669 | 2,239 |
| 30 Sep 19 | 15,658 | 1,139 | 5,646 | 2,276 |
| 30 Jun 19 | 15,354 | 1,118 | 5,640 | 2,260 |
| 31 Mar 19 | 15,096 | 938 | 5,597 | 2,245 |
| 31 Dec 18 | 14,836 | 1,071 | 5,501 | 2,226 |
| 30 Sep 18 | 14,597 | 1,921 | 5,166 | 2,157 |
| 30 Jun 18 | 14,364 | 2,218 | 5,065 | 2,152 |
| 31 Mar 18 | 14,346 | 2,389 | 5,054 | 2,127 |
| 31 Dec 17 | 14,517 | 2,548 | 5,088 | 2,107 |
| 30 Sep 17 | 14,699 | 1,787 | 5,454 | 2,085 |
| 30 Jun 17 | 14,906 | 1,628 | 5,497 | 1,991 |
| 31 Mar 17 | 15,016 | 1,529 | 5,448 | 1,975 |
| 31 Dec 16 | 15,024 | 1,629 | 5,432 | 1,976 |
| 30 Sep 16 | 14,658 | 1,480 | 5,292 | 1,824 |
| 30 Jun 16 | 14,054 | 1,387 | 5,122 | 1,798 |
| 31 Mar 16 | 13,469 | 1,418 | 5,000 | 1,757 |
| 31 Dec 15 | 12,845 | 1,109 | 4,816 | 1,709 |
| 30 Sep 15 | 12,380 | 1,269 | 4,613 | 1,738 |
| 30 Jun 15 | 12,180 | 1,154 | 4,515 | 1,826 |
| 31 Mar 15 | 11,776 | 1,114 | 4,377 | 1,765 |
| 31 Dec 14 | 11,363 | 1,157 | 4,253 | 1,704 |
| 30 Sep 14 | 11,106 | 1,158 | 4,060 | 1,627 |
| 30 Jun 14 | 10,937 | 1,249 | 4,301 | 1,501 |
| 31 Mar 14 | 10,963 | 1,261 | 3,992 | 1,480 |
| 31 Dec 13 | 11,095 | 1,202 | 3,705 | 1,507 |
양질의 수익: MRK has high quality earnings.
이익 마진 증가: MRK's current net profit margins (12.6%) are lower than last year (14%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: MRK's earnings have grown by 16.5% per year over the past 5 years.
성장 가속화: MRK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
수익 대 산업: MRK had negative earnings growth (-14.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
자기자본 수익률
높은 ROE: MRK's Return on Equity (9.2%) is considered low.